Caris scores FDA approval for multi-cancer companion diagnostic test
Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a companion diagnostic for multiple targeted medications across several | The company describes the precision medicine test as the first of its kind to offer simultaneous whole exome sequencing and whole transcriptome sequencing.